In this episode, Prof. Scott Tagawa (US), a medical oncologist at Weill Cornell Medicine in New York, discusses the results of PSMAddition - a phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. 

This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.